| Through new drug launches, panel discussions, and similar forums. | 患者权益倡导
> 药物及相关治疗 | 监管合作伙伴关系
> 与监管机构合作 | 1,000 | Regional | Sometimes | 115028447628 |
| Regular roundtables and forums are being held with the Ministry of Health and Welfare, the NHIS [국민건강보험공단 – National Health Insurance Service], HIRA [건강보험심사평가원 – Health Insurance Review and Assessment Service], the Korea Medical Research Institute, and other relevant bodies, with a view to improving the pharmaceutical pricing system. | 癌症
> 癌症：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 10,000 | National | Regularly | 114998266569 |
| We assess cost-effectiveness. | 肝脏
> 肝脏疾病：大多数类型 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Sometimes | 114998327089 |
| We nominate patient group representatives as committee members on bodies such as the HIPDC [Health Insurance Policy Deliberation Committee - 건강보험정책심의위원회] and the DREC [Drug Benefit Evaluation Committee -약제급여평가위원], and we play a role in gathering and conveying the views of patients to these bodies. | 总体健康
> 医疗服务 | 监管合作伙伴关系
> 参与卫生技术评估（HTA）和报销审查 | 100,000 | National | Regularly | 115009387424 |
| Regular roundtables and forums are being held with the Ministry of Health and Welfare, the NHIS [국민건강보험공단 – National Health Insurance Service], HIRA [건강보험심사평가원 – Health Insurance Review and Assessment Service], the Korea Medical Research Institute, and other relevant bodies, with a view to improving the pharmaceutical pricing system. | 癌症
> 癌症：大多数类型 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 10,000 | National | Regularly | 114998266569 |
| Attendance at relevant committee meetings and informal consultative sessions. | 先天性
> 先天性：心脏 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 10,000 | National | Rarely | 115003445044 |
| Activities include policy forums, stakeholder consultations, meetings with relevant government ministries, and related engagements. | 稀有
> 罕见病：大多数类型 | 监管合作伙伴关系
> 参加/主持与政策制定者/监管机构的会议 | 1,000 | National | Regularly | 115033450975 |
| Convening public hearings in the National Assembly and submitting formal recommendations to the Ministry of Health and Welfare [in Korea]. | 心理健康
> 心理健康：大多数状况 | 影响政策和立法
> 影响医疗保健政策和立法 | 5,000 | Regional | Sometimes | 115019561629 |
| Activities included participation in policy forums advocating for the reimbursement of treatments currently excluded from public health insurance coverage, including Durvalumab and the graft-versus-host disease treatment Belumosudil. | 癌症
> 癌症：血液 | 影响政策和立法
> 参与公众听证会和咨询 | 100,000 | Regional | Sometimes | 115008918207 |
| Convening of National Assembly public hearings. | 心理健康
> 心理健康：大多数状况 | 影响政策和立法
> 参与公众听证会和咨询 | 5,000 | Regional | Sometimes | 115019561629 |
| We engage in these activities [involvement with drug-pricing regulators] when seeking reimbursement coverage for new medicines, as well as at forums and panel discussions. | 癌症
> 癌症：血液 | 影响政策和立法
> 参与公众听证会和咨询 | 1,000 | Regional | Sometimes | 115028455157 |
| Activities include participation in forums and debates, submission of petitions to the 인권위 [국가인권위원회 – National Human Rights Commission]. | 患者权益倡导
> 患者权利 | 影响政策和立法
> 参与公众听证会和咨询 | 5,000 | Regional | Regularly | 115033350867 |
| Participated in a National Assembly policy forum on medicines not covered by public health insurance to convey the patient perspective. | 癌症
> 癌症：乳腺癌 | 影响政策和立法
> 参与公众听证会和咨询 | 5,000 | National | Sometimes | 115058944486 |
| A request for the re-listing of a Parkinson's disease treatment. | 神经退行性
> 帕金森病 | 影响政策和立法
> 解决医疗保健中的障碍/异常问题 | 5,000 | National | Rarely | 115055431165 |
| Regular roundtables and forums are being held with the Ministry of Health and Welfare, the NHIS [국민건강보험공단 – National Health Insurance Service], HIRA [건강보험심사평가원 – Health Insurance Review and Assessment Service], the Korea Medical Research Institute, and other relevant bodies, with a view to improving the pharmaceutical pricing system. | 癌症
> 癌症：大多数类型 | 定价与可负担性倡导
> 倡导公平的药品定价 | 10,000 | National | Regularly | 114998266569 |
| Participated in a National Assembly policy debate on non-reimbursable drugs to convey patients' voices, and engaged in a petition drive to advocate for reimbursement coverage. | 癌症
> 癌症：乳腺癌 | 定价与可负担性倡导
> 倡导公平的药品定价 | 5,000 | National | Sometimes | 115058944486 |
| We assess cost-effectiveness. | 肝脏
> 肝脏疾病：大多数类型 | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 100,000 | National | Sometimes | 114998327089 |
| We engage in these activities [involvement with drug-pricing regulators] when seeking reimbursement coverage for new medicines, as well as at forums and panel discussions. | 癌症
> 癌症：血液 | 定价与可负担性倡导
> 参与价格审查委员会谈判 | 1,000 | Regional | Sometimes | 115028455157 |
| Reimbursement rates for basic welfare recipients. | 心理健康
> 心理健康：大多数状况 | 定价与可负担性倡导
> 解决低收入和弱势群体面临的费用障碍 | 5,000 | Regional | Sometimes | 115021952415 |
| Inclusion of medical devices — such as continuous glucose monitors and insulin pumps — on the national health insurance formulary. | 内分泌
> 糖尿病：1型 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 100,000 | National | No | 114998267322 |
| Activities included participation in policy forums advocating for the reimbursement of treatments currently excluded from public health insurance coverage, including Durvalumab [help the body's immune system recognize and destroy cancer] and the graft-versus-host disease treatment Belumosudil. | 癌症
> 癌症：血液 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 100,000 | Regional | Sometimes | 115008918207 |
| We engage in these activities [involvement with drug-pricing regulators] when seeking reimbursement coverage for new medicines, as well as at forums and panel discussions. | 癌症
> 癌症：血液 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 1,000 | Regional | Sometimes | 115028455157 |
| Participated in a National Assembly policy debate on non-reimbursable drugs to convey patients' voices, and engaged in a petition drive to advocate for reimbursement coverage. | 癌症
> 癌症：乳腺癌 | 定价与可负担性倡导
> 倡导将产品纳入报销目录/国家处方集 | 5,000 | National | Sometimes | 115058944486 |
| A request for the re-listing of a Parkinson's disease treatment. | 神经退行性
> 帕金森病 | 改善访问路径
> 促进公平获取药品/医疗保健 | 5,000 | National | Rarely | 115055431165 |
| We nominate patient group representatives as committee members on bodies such as the HIPDC [Health Insurance Policy Deliberation Committee - 건강보험정책심의위원회] and the DREC [Drug Benefit Evaluation Committee -약제급여평가위원], and we play a role in gathering and conveying the views of patients to these bodies. | 总体健康
> 医疗服务 | 循证患者意见
> 利用患者洞察来指导决策 | 100,000 | National | Regularly | 115009387424 |
| We submit written recommendations on a regular basis. | 癌症
> 癌症：血液 | 循证患者意见
> 利用患者洞察来指导决策 | 10,000 | National | Regularly | 115056090120 |
| Participated in a National Assembly policy forum on medicines not covered by public health insurance to convey the patient perspective. | 癌症
> 癌症：乳腺癌 | 循证患者意见
> 利用患者洞察来指导决策 | 5,000 | National | Sometimes | 115058944486 |
| We submit written recommendations on a regular basis. | 癌症
> 癌症：血液 | 循证患者意见
> 将证据和洞察转化为政策建议 | 10,000 | National | Regularly | 115056090120 |
| Attendance at relevant committee meetings and informal consultative sessions. | 先天性
> 先天性：心脏 | 机构治理
> 确保在政府咨询机构中的代表性 | 10,000 | National | Rarely | 115003445044 |
| We nominate patient group representatives as committee members on bodies such as the HIPDC [Health Insurance Policy Deliberation Committee - 건강보험정책심의위원회] and the DREC [Drug Benefit Evaluation Committee -약제급여평가위원], and we play a role in gathering and conveying the views of patients to these bodies. | 总体健康
> 医疗服务 | 机构治理
> 确保在政府咨询机构中的代表性 | 100,000 | National | Regularly | 115009387424 |
| Activities include participation in forums and debates, submission of petitions to the 인권위 [국가인권위원회 – National Human Rights Commission]. | 患者权益倡导
> 患者权利 | 维护患者权益/提高生活质量
> 保护/改善患者体验 | 5,000 | Regional | Regularly | 115033350867 |
互动
行动与倡导
7 提及
